The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a greater substantial reduction in body mass and improve metabolic functi